Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib, Venetoclax and Azacitidine in Newly Diagnosed FLT3 Mutated AML
NCT05520567Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jan 2023
- Primary completion
- Jul 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of gilteritinib in acute myeloid leukemia (AML), sponsored by Astellas Pharma. Started Jan 2023; status: active, not recruiting.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05520567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05520567.